Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAM-18 low-dose cytarabine study for transient abnormal myelopoiesis
jRCTs041190063Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cytarabine in transient leukemia (TAM) (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 1-year overall survival in patients who received low-dose cytarabine therapy. Started Sep 2019; status: active, not recruiting.
02
Drugs
cytarabine
03
Conditions
transient leukemia (TAM)
Beyond the preview
Go deeper on jRCTs041190063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190063.